Opportunity Information: Apply for PA 11 186
Apply for PA 11 186
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Translation of Pluripotent Stem Cell Therapies for Blood Diseases (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.839 Blood Diseases and Resources Research.
- This funding opportunity was created on Jun 10, 2011 and posted on Mar 28, 2011.
- Applicants must submit their applications by Jan 7, 2014. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Special district governments State governments Private institutions of higher education For profit organizations other than small businesses Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses Native American tribal governments (Federally recognized) City or township governments Public housing authorities/Indian housing authorities Others (see text field entitled Additional Information on Eligibility for clarification) County governments Independent school districts Public and State controlled institutions of higher education.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Foreign (non U.S.) components of U.S. Organizations are not allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
Translation of Pluripotent Stem Cell Therapies for Blood Diseases (R01) (Funding Opportunity Number: PA 11-186) is a National Institutes of Health grant opportunity led by the National Heart, Lung, and Blood Institute (NHLBI) that aims to push pluripotent stem cell science closer to real, testable cell therapies for sickle cell disease and other serious blood disorders. The opportunity supports Research Project Grant (R01) applications that bring together collaborative, multidisciplinary teams under a multi-Project Director/Principal Investigator (multi-PD/PI) structure, with the expectation that each application will name two or more PDs/PIs. The overall intent is translation-focused technology development: not just basic discovery, but the creation and refinement of methods that can realistically feed into clinical evaluation.
The FOA is built around two major technical bottlenecks that, at the time of the announcement, were limiting progress toward stem-cell-derived blood cell therapies. The first priority area is developing robust techniques to efficiently generate hematopoietic cells (blood-forming cells) in quantities and quality appropriate for clinical testing. Applicants are encouraged to address this either by differentiating human pluripotent stem cells (PSC) into hematopoietic lineages or by using cellular reprogramming approaches that convert one cell type into another with blood-forming potential. A key translational emphasis is producing sufficient numbers of cells that meet Good Manufacturing Practice (GMP) quality expectations, meaning the work should be oriented toward scalable, reproducible, and clinically compatible cell production rather than small, purely experimental batches.
The second priority area is solving the problem of efficient engraftment. Even if hematopoietic cells can be produced from PSCs or reprogramming methods, they still need to successfully engraft in a recipient and function long-term in a way that is relevant for treating disease. This FOA therefore invites projects that develop protocols, conditioning strategies, or other enabling methods that improve the ability of PSC-derived or reprogrammed hematopoietic cells to home to the right niches, persist, and contribute meaningfully to blood formation after transplantation. The underlying translational goal is to move closer to approaches that could ultimately replace or complement current transplantation strategies for disorders like sickle cell disease, where durable production of healthy blood cells is the therapeutic target.
A defining feature of this program is its explicit integration with the NHLBI Progenitor Cell Biology Consortium (PCBC). The funded projects are expected to operate in close collaboration with existing PCBC hubs, and the new awardees are also expected to collaborate extensively among themselves and with the consortium. In practical terms, this means applicants should anticipate a strong emphasis on teamwork, data and resource sharing, complementary expertise across laboratories, and coordinated progress toward shared technical goals. The FOA frames these awards as adding separate additional research projects that work alongside, and in concert with, the ongoing consortium efforts rather than operating as isolated, stand-alone studies.
From an administrative and eligibility standpoint, this is a discretionary grant mechanism using the NIH R01 funding instrument within the health-related funding activity category, tied to CFDA 93.839 (Blood Diseases and Resources Research). Cost sharing or matching is not required. Eligibility is broad and includes many types of U.S.-based and non-U.S.-based organizations, such as public and private institutions of higher education, nonprofits (including 501(c)(3) and certain non-501(c)(3) entities), for-profit organizations (including small businesses), state and local governments, tribal governments and tribally controlled institutions, and a range of mission-serving institutions such as HBCUs and Hispanic-serving institutions. Foreign organizations (non-U.S. entities) are listed as eligible, but foreign (non-U.S.) components of U.S. organizations are not allowed under this announcement, which is an important distinction for applicants with international collaborations or overseas branches.
Key timeline details in the source information show it was posted on March 28, 2011, with an original closing date of October 5, 2013, a current closing date of January 7, 2014, and an archive date of February 7, 2014. The full announcement and official details were provided through the NIH Grants Guide, with an additional information link at http://grants.nih.gov/grants/guide/pa-files/PA-11-186.html, and support contacts routed through the NIH Office of Extramural Research (OER) webmaster for access or linking issues.
Overall, the opportunity is best understood as a targeted NHLBI effort to overcome practical barriers to stem-cell-based blood therapies by funding team science that can (1) reliably produce clinically relevant, GMP-grade hematopoietic cells from PSC differentiation or reprogramming pipelines, and (2) develop engraftment-enabling protocols that make those cells therapeutically viable after transplantation, all while operating in a highly collaborative framework linked to the Progenitor Cell Biology Consortium.
FAQs: Translation of Pluripotent Stem Cell Therapies for Blood Diseases (R01) (PA-11-186)
What is this funding opportunity?
Translation of Pluripotent Stem Cell Therapies for Blood Diseases (R01) is a National Institutes of Health (NIH) grant opportunity led by the National Heart, Lung, and Blood Institute (NHLBI). It supports Research Project Grant (R01) applications aimed at moving pluripotent stem cell science closer to practical, testable cell therapy approaches for sickle cell disease and other serious blood disorders.
What is the Funding Opportunity Number (FOA number)?
The Funding Opportunity Number listed for this opportunity is PA 11-186.
Which NIH Institute is leading this FOA?
The opportunity is led by NHLBI (the National Heart, Lung, and Blood Institute), which is part of NIH.
What kind of grant mechanism is used?
This opportunity uses the NIH Research Project Grant (R01) funding instrument.
What is the main goal of the program?
The main goal is translation-focused technology development. The intent is not simply basic discovery, but developing and refining methods that can realistically support clinical evaluation of stem-cell-derived or reprogrammed blood cell therapies.
What diseases or clinical areas does the FOA emphasize?
The FOA emphasizes sickle cell disease and other serious blood disorders, with a focus on therapies that aim to produce durable, healthy blood cell formation.
Does this FOA support basic research, or is it more focused on translation?
Based on the description provided, the emphasis is strongly translational: projects are expected to tackle practical barriers and produce methods that could feed into clinical evaluation, rather than remaining at the level of small-scale, purely experimental work.
What are the two major technical bottlenecks this FOA is trying to address?
The FOA is built around two main bottlenecks: (1) robust, efficient generation of hematopoietic (blood-forming) cells in quantities and quality appropriate for clinical testing, and (2) improving efficient engraftment so the cells can successfully home, persist, and function long-term after transplantation.
What types of approaches are encouraged for generating hematopoietic cells?
Applicants are encouraged to address hematopoietic cell production either by differentiating human pluripotent stem cells (PSCs) into hematopoietic lineages or by using cellular reprogramming approaches that convert one cell type into another with blood-forming potential.
What does "GMP" mean in the context of this FOA?
The FOA highlights the need for cell production that meets Good Manufacturing Practice (GMP) quality expectations. In this context, that means applicants should orient their work toward scalable, reproducible, clinically compatible production methods rather than small, one-off experimental batches.
Is scalability and reproducibility explicitly important for proposed methods?
Yes. The FOA explicitly emphasizes producing sufficient numbers of cells and doing so in a way that is scalable, reproducible, and compatible with clinical expectations (including GMP-oriented considerations).
What does the FOA mean by "engraftment" challenges?
Engraftment refers to the ability of transplanted hematopoietic cells to successfully home to the correct biological niches in a recipient, persist over time, and contribute meaningfully to blood formation. The FOA calls for methods that improve these outcomes for PSC-derived or reprogrammed hematopoietic cells.
What kinds of engraftment-related solutions does the FOA invite?
The FOA invites projects that develop protocols, conditioning strategies, or other enabling methods that improve homing, persistence, and long-term function of PSC-derived or reprogrammed hematopoietic cells after transplantation.
How is collaboration structured for this program?
A defining feature is integration with the NHLBI Progenitor Cell Biology Consortium (PCBC). Funded projects are expected to operate in close collaboration with existing PCBC hubs, collaborate among themselves, and coordinate progress toward shared technical goals.
What is the NHLBI Progenitor Cell Biology Consortium (PCBC) role here?
The FOA frames new awards as additional research projects that work alongside, and in concert with, ongoing PCBC efforts. Applicants should expect strong emphasis on teamwork, sharing of data and resources, complementary expertise across laboratories, and coordinated progress.
Are applications expected to be stand-alone projects?
No. The FOA describes these awards as operating in a highly collaborative framework aligned with the PCBC, rather than as isolated, stand-alone studies.
Does the FOA require a multi-PD/PI structure?
Yes. The FOA expects applications to use a multi-Project Director/Principal Investigator (multi-PD/PI) structure, with the expectation that each application will name two or more PDs/PIs.
How many PDs/PIs should be named on an application?
The FOA expectation stated in the provided information is that each application will name two or more PDs/PIs.
Is cost sharing or matching required?
No. The provided information states that cost sharing or matching is not required.
What is the CFDA number associated with this opportunity?
The opportunity is tied to CFDA 93.839, identified as Blood Diseases and Resources Research.
Who is eligible to apply?
Eligibility is described as broad. It includes many types of U.S.-based and non-U.S.-based organizations, including public and private institutions of higher education, nonprofits (including 501(c)(3) and certain non-501(c)(3) entities), for-profit organizations (including small businesses), state and local governments, tribal governments and tribally controlled institutions, and mission-serving institutions such as HBCUs and Hispanic-serving institutions.
Are foreign (non-U.S.) organizations eligible?
Yes. Foreign organizations (non-U.S. entities) are listed as eligible in the provided information.
Are foreign (non-U.S.) components of U.S. organizations allowed?
No. The provided information states that foreign (non-U.S.) components of U.S. organizations are not allowed under this announcement. This is distinct from the eligibility of foreign organizations themselves.
Where can applicants find the official announcement?
The official details were provided through the NIH Grants Guide. The additional information link given is: http://grants.nih.gov/grants/guide/pa-files/PA-11-186.html
What are the key dates listed for this FOA?
The source information lists: posted on March 28, 2011; original closing date of October 5, 2013; current closing date of January 7, 2014; and archive date of February 7, 2014.
Is this opportunity still open?
Based on the dates provided, the FOA has a closing date of January 7, 2014 and an archive date of February 7, 2014, indicating it is not a current open opportunity according to the listed timeline.
Who should be contacted for access or linking issues?
The provided information indicates support contacts are routed through the NIH Office of Extramural Research (OER) webmaster for access or linking issues.
What does "translation-focused technology development" mean here?
In this FOA, it means developing practical methods and enabling technologies that can realistically advance toward clinical evaluation, especially around producing clinically relevant hematopoietic cells (including GMP-oriented production) and improving engraftment after transplantation.
What is the overall theme of the funded work?
The overall theme is overcoming practical barriers to stem-cell-based blood therapies through team science that (1) reliably produces clinically relevant hematopoietic cells from PSC differentiation or reprogramming pipelines and (2) develops engraftment-enabling protocols, all within a consortium-linked collaborative framework.
Browse more opportunities from the same category: Health
Next opportunity: Annual Surveys of Jails in Indian Country, 2012 2015
Previous opportunity: Office of Postsecondary Education (OPE) Erma Byrd Scholarship Program CFDA Number 84.116E
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 11 186
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 11 186) also looked into and applied for these:
| Funding Opportunity |
|---|
| A National Coalition to Enhance STD/HIV Prevention through Promotion of a Holistic Approach to Health and Wellness Apply for CDC RFA PS11 1112 Funding Number: CDC RFA PS11 1112 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $135,000 |
| Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery (UM1) Apply for RFA AI 11 002 Funding Number: RFA AI 11 002 Agency: National Institutes of Health Category: Health Funding Amount: $19,000,000 |
| Initiatives to Educate State Officials and Policy Makers about Priority Public Health Issues Related to the Prevention and Control of Sexually Transmitted Diseases (STDs) and Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome ( Apply for CDC RFA PS11 1118 Funding Number: CDC RFA PS11 1118 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $250,000 |
| Eliminating Mother to Child HIV Transmission in the United States through Continuous Quality Improvement The FIMR HIV Prevention Methodology Apply for CDC RFA PS11 1116 Funding Number: CDC RFA PS11 1116 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| PPHF 2012 Immunization Capacity Building Assistance to Strengthen Public Health Immunization Infrastructure and Performance financed in part by 2012 Prevention and Public Health Funds Apply for CDC RFA IP11 1107PPHF11 Funding Number: CDC RFA IP11 1107PPHF11 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Next Generation PrEP II (R01) Apply for RFA AI 11 023 Funding Number: RFA AI 11 023 Agency: National Institutes of Health Category: Health Funding Amount: $300,000 |
| Cooperative Agreements for Screening, Brief Intervention and Referral to Treatment Apply for TI 11 005 Funding Number: TI 11 005 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $1,666,000 |
| Limited Competition for the Continuation of Rare Diseases Clinical Research Consortia in the Rare Diseases Clinical Research Network (U54) Apply for PAR 11 187 Funding Number: PAR 11 187 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Optimizing Fidelity of Empirically Supported Behavioral Treatments for Mental Disorders (R21/R33) Apply for RFA MH 12 050 Funding Number: RFA MH 12 050 Agency: National Institutes of Health Category: Health Funding Amount: $225,000 |
| Strengthening Angolan Systems for Health (SASH) Apply for RFA674 11 32 Funding Number: RFA674 11 32 Agency: South Africa USAID Pretoria Category: Health Funding Amount: $33,000,000 |
| Support of NIAMS Program Project Grants (P01) Apply for PAR 11 188 Funding Number: PAR 11 188 Agency: National Institutes of Health Category: Health Funding Amount: $1,000,000 |
| Dental Reimbursement Program Apply for HRSA 11 097 Funding Number: HRSA 11 097 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Public Health Prevention Fund Streamlined Surveillance for Ventilator Associated Pneumonia Reducing Burden and Demonstrating Preventability Apply for CDC RFA CK11 0010101PPHF11 Funding Number: CDC RFA CK11 0010101PPHF11 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,508,825 |
| Public Prevention Health Fund Pacific Islands Supplemental Funding for Five Year US Affiliated Pacific Island Collaborative Performance Agreement for Tobacco Control, Diabetes Prevention and Control, and the Behavioral Risk Factor Surveillance System Apply for CDC RFA DP09 9020302PPHF11 Funding Number: CDC RFA DP09 9020302PPHF11 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $50,000 |
| Integrating Multi Dimensional Data to Explore Mechanisms Underlying Mental Disorders (RO1) Apply for RFA MH 12 020 Funding Number: RFA MH 12 020 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Program for Extramural/Intramural Alcohol Research Collaborations (U01) Apply for PAR 11 189 Funding Number: PAR 11 189 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Public Prevention Health Fund State Supplemental Funding for Healthy Communities, Tobacco Prevention and Control, Diabetes Prevention and Control, and Behavioral Risk Factor Surveillance System Apply for CDC RFA DP09 9010201PPHF11 Funding Number: CDC RFA DP09 9010201PPHF11 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| State Implementation Grants for Improving Services for Children and Youth with ASD Apply for HRSA 11 071 Funding Number: HRSA 11 071 Agency: Health Resources and Services Administration Category: Health Funding Amount: $300,000 |
| State Implementation Planning Grants for Improving Services for Children and Youth with ASD Apply for HRSA 11 081 Funding Number: HRSA 11 081 Agency: Health Resources and Services Administration Category: Health Funding Amount: $75,000 |
| Control of NTD ENVISION Apply for RFA OAA 11 000007 Funding Number: RFA OAA 11 000007 Agency: Agency for International Development Category: Health Funding Amount: $250,000,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 11 186", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.